Here, our results indicated that patients with high FERMT1 expression were more sensitive to Palbociclib, AM-5992 and TAE-226, which could serve as drug candidates for combination therapy to improve pancreatic cancer treatment. Here, FERMT1 is linked to familial pancreatic carcinoma.